Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales
Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...
What is B. Riley’s Forecast for Geron FY2025 Earnings?
B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Geron in a research report issued to clients ...
Geron Shares Drop After Wider-Than-Expected 4Q Loss
Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.
Geron stock tumbles on disappointing guidance
Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company's net product revenue for RYTELO reached $47.5 million in ...
Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy?
We recently published a list of 10 Best Nasdaq Stocks Under $5 to Buy. In this article, we are going to take a look at where Geron Corp. (NASDAQ:GERN) stands against other best Nasdaq stocks under $5 ...
Business Wire7d
Geron to Participate at Upcoming Investor Conferences in March 2025
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled to p ...
Geron stock plunges 30% amid Rytelo sales concerns (update)
Shares of Geron (NASDAQ:GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Geron reported a ...